| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/AJKD.2000.16193 |
| P698 | PubMed publication ID | 10977787 |
| P50 | author | João M Frazão | Q59088695 |
| P2093 | author name string | W G Goodman | |
| R B Mazess | |||
| J A Robertson | |||
| J W Coburn | |||
| L Elangovan | |||
| J D Bower | |||
| R W Chesney | |||
| B S Levine | |||
| C W Bishop | |||
| D M Kyllo | |||
| K C Norris | |||
| S R Acchiardo | |||
| D Gentile | |||
| B J Kelley | |||
| H J Rodriguez | |||
| H M Maung | |||
| L L Douglass | |||
| P433 | issue | 3 | |
| P921 | main subject | secondary hyperparathyroidism | Q3622611 |
| P304 | page(s) | 550-561 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism | |
| P478 | volume | 36 |
| Q46318585 | 1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism |
| Q35682192 | A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM) |
| Q35117084 | An update on the therapeutic potential of vitamin D analogues |
| Q35553309 | An update on vitamin D as related to nephrology practice: 2003 |
| Q36947391 | Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results |
| Q35026470 | Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis |
| Q38685730 | Effects of vitamin D or its analogues on the mortality of patients with chronic kidney disease: an updated systematic review and meta-analysis |
| Q37091145 | Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4 |
| Q46399532 | Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis |
| Q36561062 | Minimizing bone abnormalities in children with renal failure |
| Q79190034 | Mortality risk among hemodialysis patients receiving different vitamin D analogs |
| Q44894697 | New Vitamin D analogues for osteodystrophy in chronic kidney disease |
| Q26825692 | Nuclear receptors and their selective pharmacologic modulators |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q35553301 | Overview of renal bone disease: Causes of treatment failure, clinical observations, the changing pattern of bone lesions, and future therapeutic approach |
| Q38824573 | Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease |
| Q35568749 | Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment |
| Q24240582 | Vitamin D compounds for people with chronic kidney disease requiring dialysis |
| Q37089710 | Vitamin D receptor activation and survival in chronic kidney disease. |
| Q34621641 | Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. |
| Q35020986 | Vitamin d receptor activators and clinical outcomes in chronic kidney disease. |
Search more.